The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1605
ISSUE1605
August 24, 2020
Ozanimod (Zeposia) for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ozanimod (Zeposia) for Multiple Sclerosis
August 24, 2020 (Issue: 1605)
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.